ECCO'25 Abstracts

ECCO'25 Abstracts on the JCC Website

ECCO'25 Abstract Book PDF Version

ECCO'25 Abstracts COI Disclosure

ECCO'24 Abstracts

ECCO'24 Abstracts on the JCC Website

ECCO'24 Abstract Book PDF Version

ECCO'24 Abstracts COI Disclosure

DOP Session 6 - Real-world evidence and pregnancy

DOP46 Sustainability rate of immunomodulators monotherapy in patients with Crohn's Diseases: A population-based analysis from the epi-IIRN cohort

DOP47 Real World Evidence on the effectiveness of ustekinumab in Crohn’s Disease: Induction phase results from the prospective, observational RUN-CD Study

DOP48 Use of biologic therapies with different mechanisms of action (MOA) in the first-line (1L) treatment of Crohn’s Disease (CD) in the U.S.

DOP49 Effectiveness and safety of vedolizumab in a matched cohort of elderly and young Inflammatory Bowel Disease patients - LIVE Study-Group

DOP50 Recommencement of Inflammatory Bowel Disease medications following colectomy for Ulcerative Colitis

DOP51 De-escalation of biological therapy in Inflammatory Bowel Disease patients following prior escalation

DOP52 Safety of Inflammatory Bowel Disease drugs during pregnancy and breastfeeding: Mothers and babies’ outcomes (DUMBO registry)

DOP53 Pregnancy outcomes in the ozanimod clinical development program in relapsing multiple sclerosis, Ulcerative Colitis, and Crohn’s Disease

DOP54 Real-world effectiveness of thiopurine monotherapy in Crohn’s Disease: Is there still a place for thiopurines in the biological era?